Protein and microRNA Markers for Early Detection of Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-07

Study Completion Date

2020-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Blood will be harvested from three groups of people, normal control, patients with mild cognitive impairment (MCI) and patients with Alzheimer's disease (AD), 20 people per group. The blood samples will be used to determine the difference in the expression of microRNAs and proteins. Blood samples will be harvested again at 6-month interval from patients. The combination of the microRNAs and proteins that have different expression patterns between normal control and patients with MCI will be constructed in a kit to detect the difference. This kit will be used in another set of the three groups of people to determine its sensitivity and specificity in detecting patients with MCI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Digital Technology Combined With Blood Marker Screening and Diagnosis for Community Populations Based on Classification Theory: an Integrated Study

NCT07286812

Alzheimer Disease

NOT_YET_RECRUITING

China Alzheimer's and Neurodegenerative Disorder Research

NCT04320368

Cognitive Impairment

UNKNOWN

Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease

NCT06856681

Alzheimers Disease

WITHDRAWN NA

Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease

NCT06442852

Alzheimer Disease MicroRNAs

RECRUITING

Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia

NCT02686554

Alzheimer Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As discussed above, patients' blood samples will be tested by chip to test microRNA expression and liquid chromatography-mass spectrometry to determine protein expression. The differences in microRNA and protein expression among the three groups, especially between the control and MCI, will be analyzed. This information will be used to construct a kit that can contain probes to detect a few microRNAs or proteins. This kit will be used in another set of patients to check its sensitivity and specificity. The first set of patients will also be followed up every 6 months for up to 1.5 years. Blood samples will be harvested during the follow-ups. The changes in microRNAs and proteins will be correlated with the changes of cognition. This information will be used for constructing the kit as well.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

* Age-matched with patients with MCI group

Exclusion Criteria

* With cognitive dysfunction
* With major cardiovascular diseases, especially stroke and brain transient ischemic attack
* On steroid treatment
* with major organ diseases

Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes